HDAC9 and hematologic disorder: An HDAC6/JAK2 inhibitor was designed based on vorinostat and pacritinib, and showed preclinical efficacy in AML and ALL.694 CUDC-907, an HDAC/PI3K inhibitor, exerted an ORR of 37% in R/R DLBCL patients, including those with MYC-alterations.695 HDAC/LSD1 inhibitors and HDAC I/tubulin inhibitors display favorable efficacy in solid tumors, such as colon cancer and breast cancer, but few studies have explored their application to hematologic malignancies.696,697